Cargando…

Immunosedation: a consideration for sepsis

In a recent issue of Critical Care, Qiao and colleagues showed in a rat model of sepsis that dexmedetomidine and midazolam suppress the generation of pro-inflammatory mediators but the effects vary between agents. While dexmedetomidine limited apoptosis to a greater extent than midazolam, both agent...

Descripción completa

Detalles Bibliográficos
Autor principal: MacLaren, Robert
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784358/
https://www.ncbi.nlm.nih.gov/pubmed/19889196
http://dx.doi.org/10.1186/cc8034
_version_ 1782174731488722944
author MacLaren, Robert
author_facet MacLaren, Robert
author_sort MacLaren, Robert
collection PubMed
description In a recent issue of Critical Care, Qiao and colleagues showed in a rat model of sepsis that dexmedetomidine and midazolam suppress the generation of pro-inflammatory mediators but the effects vary between agents. While dexmedetomidine limited apoptosis to a greater extent than midazolam, both agents significantly reduced short-term mortality compared with saline. This study, in addition to those by others, suggests there are disparate immunomodulating effects between sedatives. Clinical studies are warranted to investigate whether these effects impact outcomes of septic patients. Perhaps one day the choice of sedative in septic patients will not be based solely on sedative properties but rather immunosedative profiles.
format Text
id pubmed-2784358
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27843582010-10-06 Immunosedation: a consideration for sepsis MacLaren, Robert Crit Care Commentary In a recent issue of Critical Care, Qiao and colleagues showed in a rat model of sepsis that dexmedetomidine and midazolam suppress the generation of pro-inflammatory mediators but the effects vary between agents. While dexmedetomidine limited apoptosis to a greater extent than midazolam, both agents significantly reduced short-term mortality compared with saline. This study, in addition to those by others, suggests there are disparate immunomodulating effects between sedatives. Clinical studies are warranted to investigate whether these effects impact outcomes of septic patients. Perhaps one day the choice of sedative in septic patients will not be based solely on sedative properties but rather immunosedative profiles. BioMed Central 2009 2009-10-06 /pmc/articles/PMC2784358/ /pubmed/19889196 http://dx.doi.org/10.1186/cc8034 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Commentary
MacLaren, Robert
Immunosedation: a consideration for sepsis
title Immunosedation: a consideration for sepsis
title_full Immunosedation: a consideration for sepsis
title_fullStr Immunosedation: a consideration for sepsis
title_full_unstemmed Immunosedation: a consideration for sepsis
title_short Immunosedation: a consideration for sepsis
title_sort immunosedation: a consideration for sepsis
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784358/
https://www.ncbi.nlm.nih.gov/pubmed/19889196
http://dx.doi.org/10.1186/cc8034
work_keys_str_mv AT maclarenrobert immunosedationaconsiderationforsepsis